The Baltimore Museum of Art today announced that it has acquired more than 200 works across its encyclopedic collection.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Beth Fukumoto served three terms in the Hawaiʻi House of Representatives. She was the youngest woman in the U.S. to lead a major party in a legislature, the first elected Republican to switch ...

Beth Fukumoto served three terms in the Hawaii House of Representatives where she was recognized as one of Washington Post’s “40 under 40″ rising political stars, Business Insider’s “8 ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The current price of Dai (DAI) is $0.999977, as of Apr 4, 2025. Over the last 24 hours, the price has moved by 0%, with a change of 0.01% in the past hour. For longer-term performance, the price has ...

Dai-ichi Life Holdings Inc. said a US subsidiary agreed to transfer insurance blocks totaling about $9.7 billion in policy reserves to a reinsurance firm to improve earnings. Protective Life Corp., ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

(Bloomberg) -- Dai-ichi Life Holdings Inc. said a US subsidiary agreed to transfer insurance blocks totaling about $9.7 billion in policy reserves to a reinsurance firm to improve earnings.

Dai-ichi Life Holdings Inc. announced that its US subsidiary, Protective Life Corporation, has entered into a strategic reinsurance agreement with Resolution Life Group Holdings Ltd. The deal will ...

Japan's health gains over the past 30 years are now stalling, with rising regional disparities. The increasing burdens of ...